Harbour Capital Advisors LLC Cuts Position in Eli Lilly and Company (NYSE:LLY)

by · The Markets Daily

Harbour Capital Advisors LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,556 shares of the company’s stock after selling 186 shares during the quarter. Eli Lilly and Company accounts for approximately 3.9% of Harbour Capital Advisors LLC’s portfolio, making the stock its largest position. Harbour Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $17,067,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Lynx Investment Advisory purchased a new position in Eli Lilly and Company during the 2nd quarter worth $32,000. LGT Financial Advisors LLC purchased a new stake in Eli Lilly and Company in the second quarter worth $36,000. Cedar Mountain Advisors LLC raised its stake in Eli Lilly and Company by 53.3% in the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after acquiring an additional 16 shares during the period. Morton Brown Family Wealth LLC lifted its stake in shares of Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after buying an additional 15 shares in the last quarter. Finally, Unique Wealth Strategies LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $45,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $917.18 on Friday. The company has a 50-day simple moving average of $920.70 and a two-hundred day simple moving average of $856.27. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The firm has a market cap of $871.69 billion, a price-to-earnings ratio of 135.08, a PEG ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on LLY shares. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Bank of America increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Citigroup began coverage on shares of Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target for the company. Finally, Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $986.00.

Read Our Latest Stock Report on Eli Lilly and Company

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).